Form 4: CalciMedica CFO Acquires Stock Options

CalciMedica, Inc. reports that Chief Financial Officer Stephen Bardin acquired employee stock options on April 5, 2026.

Summary

• Stephen Bardin, Chief Financial Officer of CalciMedica, Inc., acquired employee stock options on April 5, 2026.
• The options grant the right to buy 67,728 shares of common stock at an exercise price of $0.585 per share.
• Vesting of these options is scheduled to begin on April 1, 2026, with 1/48th of the shares vesting monthly over four years.
• However, no shares will vest until CalciMedica files its Form S-8 registration statement for shares added to the 2023 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily details a standard executive stock option grant with a condition for vesting, rather than indicating significant new financial performance or strategic shifts.

Positives

• The CFO's acquisition of stock options may indicate confidence in the company's future performance.
• The option grant provides a potential incentive for the CFO to align their interests with shareholders.

Negatives

• The vesting of the acquired options is contingent upon the company filing a Form S-8, which has not yet occurred.
• The earliest transaction date listed is April 5, 2026, but the filing date is April 7, 2026, indicating a slight delay in reporting.

Risks

• The vesting of the stock options is dependent on the company successfully filing a Form S-8 registration statement, which could be subject to delays or regulatory scrutiny.
• The company's ability to execute its business plan and achieve milestones necessary to support its stock price is a general risk.

Future Outlook

The vesting of the acquired stock options is contingent on the company filing a Form S-8 registration statement, which is a prerequisite for the shares to become available. The specific timeline for this filing is not provided, but it is a critical step for the options to vest.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a Chief Financial Officer is a common practice in the biotechnology and pharmaceutical sectors, often used as a long-term incentive to retain key executives and align their interests with shareholders, especially during periods of development and potential future growth.

Stakeholder Impact

• Shareholders: The grant of options to the CFO, while standard, represents potential future dilution if exercised. The contingent vesting also highlights a procedural step the company needs to complete.
• Employees: The 2023 Equity Incentive Plan, which includes the shares subject to this option grant, is a mechanism for employee compensation and retention.
• Management: The CFO, Stephen Bardin, has been granted an incentive tied to the company's stock performance, contingent on regulatory filings.

Next Steps

• CalciMedica, Inc. must file a Form S-8 registration statement covering the shares of Common Stock authorized under its 2023 Equity Incentive Plan.
• Upon filing of the Form S-8, the vesting of Stephen Bardin's stock options will commence, with 1/48th vesting monthly over four years.

Key Dates

Keywords

CalciMedica, CALC, Form 4, Stock Options, Insider Trading, Executive Compensation, Securities, SEC Filing, Stephen Bardin, CFO